{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:37:06Z","timestamp":1793723826205,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.gore.2023.101293","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T21:22:45Z","timestamp":1697491365000},"page":"101293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Health state utility and health-related quality of life measures in patients with advanced ovarian cancer"],"prefix":"10.1016","volume":"50","author":[{"given":"Ruby M.","family":"van Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florine J.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca P.","family":"Ret\u00e8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor D.","family":"de Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christianne A.R.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"de Ligt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemien J.","family":"van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gore.2023.101293_b0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl Cancer Inst."},{"issue":"6","key":"10.1016\/j.gore.2023.101293_b0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial","volume":"34","author":"Basch","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101293_b0015","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ygyno.2007.05.043","article-title":"Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis","volume":"106","author":"Bristow","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2023.101293_b0020","doi-asserted-by":"crossref","first-page":"448","DOI":"10.6004\/jnccn.2008.0036","article-title":"Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy","volume":"6","author":"Butt","year":"2008","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"4","key":"10.1016\/j.gore.2023.101293_b0025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1586\/erp.11.41","article-title":"Health-related quality of life in ovarian cancer patients and its impact on clinical management","volume":"11","author":"Chase","year":"2011","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"1","key":"10.1016\/j.gore.2023.101293_b0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12955-018-0857-3","article-title":"Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement","volume":"16","author":"Dakin","year":"2018","journal-title":"Health Qual. Life Outcomes"},{"issue":"9","key":"10.1016\/j.gore.2023.101293_b0035","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx029","article-title":"Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients","volume":"109","author":"Denis","year":"2017","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.gore.2023.101293_b0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gore.2023.101293_b0045","unstructured":"Fayers PM, A.N., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., 2001. On behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual, 3rd ed. Published by: European Organisation for Research and Treatment of Cancer, Brussels."},{"key":"10.1016\/j.gore.2023.101293_b0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/CEOR.S91844","article-title":"Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer","volume":"8","author":"Forde","year":"2016","journal-title":"Clinicoecon. Outcomes Res."},{"key":"10.1016\/j.gore.2023.101293_b0055","article-title":"Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer","volume":"223(5):725.e1-.e9","author":"Frey","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.gore.2023.101293_b0060","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1470-2045(21)00098-X","article-title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","volume":"22","author":"Friedlander","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gore.2023.101293_b0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","article-title":"Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust","volume":"69","author":"Giesinger","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.gore.2023.101293_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","article-title":"Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research","volume":"118","author":"Giesinger","year":"2020","journal-title":"J. Clin. Epidemiol."},{"issue":"10","key":"10.1016\/j.gore.2023.101293_b0075","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"25","key":"10.1016\/j.gore.2023.101293_b0080","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1200\/JCO.2007.13.1961","article-title":"Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"26","author":"Havrilesky","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2023.101293_b0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","article-title":"Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment","volume":"113","author":"Havrilesky","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.gore.2023.101293_b0090","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1200\/OP.20.00752","article-title":"Evaluating mental health-related symptoms among cancer survivors during the COVID-19 pandemic: an analysis of the COVID impact survey","volume":"17","author":"Islam","year":"2021","journal-title":"JCO Oncol Pract."},{"issue":"9990","key":"10.1016\/j.gore.2023.101293_b0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gore.2023.101293_b0100","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.3802\/jgo.2022.33.e54","article-title":"Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)","volume":"33","author":"Kim","year":"2022","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.gore.2023.101293_b0105","article-title":"Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer","author":"Koole","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.gore.2023.101293_b0110","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/ijgc-2018-000125","article-title":"Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Kumar","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.gore.2023.101293_b0115","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/ijgc-2021-003142","article-title":"Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study","volume":"32","author":"Lee","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.gore.2023.101293_b0120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2011.05.014","article-title":"Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer","volume":"122","author":"Lesnock","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2023.101293_b0125","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jval.2012.10.010","article-title":"Mapping to obtain EQ-5D utility values for use in NICE health technology assessments","volume":"16","author":"Longworth","year":"2013","journal-title":"Value Health"},{"issue":"22","key":"10.1016\/j.gore.2023.101293_b0130","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2023.101293_b0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.gore.2023.101293_b0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.gore.2023.101293_b0145","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2006.09.007","article-title":"Putting the 'Q' in quality adjusted life years (QALYs) for advanced ovarian cancer - an approach using data clustering methods and the internet","volume":"43","author":"Stein","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.gore.2023.101293_b0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ncponc0693","article-title":"Quality of life for patients with epithelial ovarian cancer","volume":"4","author":"Sun","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"7","key":"10.1016\/j.gore.2023.101293_b0155","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/1471-0528.17041","article-title":"Quality of life from cytoreductive surgery in advanced ovarian cancer: investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study","volume":"129","author":"Sundar","year":"2022","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.gore.2023.101293_b0160","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.gore.2023.101293_b0165","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2012.08.032","article-title":"Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients","volume":"127","author":"Uppal","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2023.101293_b0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaoncol.2020.6093","article-title":"Perceived care and well-being of patients with cancer and matched norm participants in the COVID-19 CRISIS: RESULTS OF A SURVEY OF PARTICIPANTS in the Dutch PROFILES registry","volume":"7","author":"van de Poll-Franse","year":"2021","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101293_b0175","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ygyno.2017.06.019","article-title":"Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer","volume":"146","author":"van de Vrie","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2023.101293_b0180","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2023.101293_b0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.gore.2023.101293_b0190","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41398-020-00950-y","article-title":"Epidemiology of mental health problems among patients with cancer during COVID-19 pandemic","volume":"10","author":"Wang","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.gore.2023.101293_b0195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1634\/theoncologist.2017-0297","article-title":"A Systematic review of health-related quality of life reporting in ovarian cancer phase III clinical trials: room to improve","volume":"23","author":"Wilson","year":"2018","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.gore.2023.101293_b0200","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","article-title":"Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report","volume":"19","author":"Wolowacz","year":"2016","journal-title":"Value Health"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923003107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923003107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:58:58Z","timestamp":1762480738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923003107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":40,"alternative-id":["S2352578923003107"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101293","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health state utility and health-related quality of life measures in patients with advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101293"}}